After Tripling GS Base, Doubling Revenue In 2006, 454 Aims for Profitability in 2007 | GenomeWeb
454 Life Sciences exceeded revenue targets for 2006 and is on track to become profitable next year, its parent company CuraGen said last week.
Although an inventory transition from the Genome Sequencer 20 to the newly launched FLX caused most of a 25-percent drop in 454’s instrument and reagent revenues in the fourth quarter, distribution partner Roche had a “record quarter” for instrument sales, CuraGen said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.